Hypertriglyceridemia Drug Pipeline Analysis Report 2025

Hypertriglyceridemia is a condition characterized by elevated triglyceride levels in the blood, increasing the risk of cardiovascular diseases and pancreatitis. It accounts for around 4% to 10% of all acute pancreatitis cases globally. There is a high unmet clinical need for better therapies, as current treatment options, such as fibrates and omega-3 fatty acids, have limitations. The growing focus on novel hypertriglyceridemia therapeutics, including APOC3 and ANGPTL3 inhibitors, is likely to drive pipeline growth in the coming years.

Report Coverage

The Hypertriglyceridemia Drug Pipeline Insight Report by the publisher gives comprehensive insights into hypertriglyceridemia therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for hypertriglyceridemia. The hypertriglyceridemia report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The hypertriglyceridemia pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with hypertriglyceridemia treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to hypertriglyceridemia.

Hypertriglyceridemia Drug Pipeline Outlook

Hypertriglyceridemia is a condition characterized by abnormally high triglyceride levels in the blood, increasing the risk of cardiovascular disease and acute pancreatitis. It occurs due to genetic factors, obesity, diabetes, excessive alcohol intake, and a high-fat diet. Insulin resistance and metabolic disorders can also contribute to hypertriglyceridemia by impairing lipid metabolism, leading to excessive triglyceride accumulation in the bloodstream.

Hypertriglyceridemia treatment includes lifestyle modifications such as a low-fat diet, regular exercise, and weight management. Medications like fibrates, omega-3 fatty acids, and statins help lower triglyceride levels. Emerging drug candidates offer promising therapeutic potential. Advancements in gene-based and targeted therapies continue to improve hypertriglyceridemia management and patient outcomes.

Hypertriglyceridemia Epidemiology

Hypertriglyceridemia accounts for 4% to 10% of all acute pancreatitis (AP) cases globally. In the United States, 26.8 million adults have moderate hypertriglyceridemia (200-499 mg/dL), while 2.3 million have severe hypertriglyceridemia (=500 mg/dL. Severe hypertriglyceridemia is associated with central obesity (70.3%), diabetes (32.7%), and chronic kidney disease (21.6%). In the United Kingdom, familial hypertriglyceridemia affects approximately 1% of the population.

Hypertriglyceridemia - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of hypertriglyceridemia drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Monoclonal Antibodies
• Gene Therapies
• RNA-based Therapies
• Peptides

By Route of Administration

• Oral
• Parenteral
• Others

Hypertriglyceridemia - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III covers a major share of the total hypertriglyceridemia clinical trials.

Hypertriglyceridemia - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the hypertriglyceridemia pipeline analysis include small molecules, monoclonal antibodies, gene therapies, RNA-based therapies, and peptides. The hypertriglyceridemia report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for hypertriglyceridemia.

Hypertriglyceridemia Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the hypertriglyceridemia drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed hypertriglyceridemia therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in hypertriglyceridemia clinical trials:

• OrsoBio, Inc.
• Ionis Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals
• Kylonova (Xiamen) Biopharma Co., Ltd.
• NorthSea Therapeutics B.V.
• Zhejiang Doer Biologics Co., Ltd.
• MediciNova
• 89bio, Inc.
• Genecradle Therapeutics Co., Ltd.
• Explore Ikaria Bioscience Pty Ltd.

Hypertriglyceridemia Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for hypertriglyceridemia. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of hypertriglyceridemia drug candidates.

Drug: Plozasiran Injection

Plozasiran (ARO-APOC3) is being evaluated in a Phase III study sponsored by Arrowhead Pharmaceuticals. The study is assessing the safety and efficacy of Plozasiran in adults with hypertriglyceridemia. It is expected to be completed by October 2026, it will enroll approximately 1,328 participants receiving either Plozasiran or a placebo.

Drug: DR10624 Injection

The DR10624 drug candidate is being evaluated in a Phase II clinical trial sponsored by Zhejiang Doer Biologics Co., Ltd. The study is designed to assess the efficacy and safety of DR10624 in patients with severe hypertriglyceridemia (SHTG). The trial will focus on how effectively DR10624 manages triglyceride levels and its safety profile in individuals with this condition. With an estimated enrollment of 72 participants, the trial is expected to conclude by October 2025.

Drug: Kylo-12

Kylo-12 is currently being evaluated in a Phase 1 clinical study for hypertriglyceridemia. The study sponsored by Kylonova (Xiamen) Biopharma Co., Ltd., aims to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects. With around 50 participants, the trial is expected to be completed by August 30, 2026.

Reasons To Buy This Report

The Hypertriglyceridemia Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for hypertriglyceridemia. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into hypertriglyceridemia collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Hypertriglyceridemia - Pipeline Insight Report

• Which companies/institutions are leading the hypertriglyceridemia drug development?
• What is the efficacy and safety profile of hypertriglyceridemia pipeline drugs?
• Which company is leading the hypertriglyceridemia pipeline development activities?
• What is the current hypertriglyceridemia commercial assessment?
• What are the opportunities and challenges present in the hypertriglyceridemia drug pipeline landscape?
• What is the efficacy and safety profile of hypertriglyceridemia pipeline drugs?
• Which company is conducting major trials for hypertriglyceridemia drugs?
• Which companies/institutions are involved in hypertriglyceridemia collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in hypertriglyceridemia?

This product will be delivered within 3-5 business days.